Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GLUE with free AI briefings, catalyst countdowns, and dilution alerts.

GLUE · Monte Rosa Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$577.7M Cash on Hand
40.7mo Cash Runway
24.8% Short Interest
$25.38 Analyst Target (8)
Follow GLUE by email Get an email when GLUE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GLUE, unsubscribe in one click. Privacy

📣 What GLUE Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
GSPT1 MGD MRT-2359 Castration-Resistant Prostate Cancer (CRPC) Phase 2 · NCT07745361 Recruiting
MRT-6160 Healthy Volunteers Phase 1 · NCT06597799 Completed
MRT-8102 Healthy Volunteers Phase 1 · NCT07119125 Active not recruiting

Also used in these trials (approved or third-party drugs, not GLUE's own candidates): Temozolomide, Apalutamide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GLUE holds $577.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $42.5M/quarter from operations, an estimated runway of 40.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 39 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GLUE files for a raise →

👥 Who Owns GLUE

Insiders 15.5% Other 5%+ holders 15.5% Institutions (261 holders) 69% Public and other holders 0%
HolderTypeShares% of sharesAs of
Baker Bros. Advisors LP Institution (13G, 5%+) 8,876,346 10.39% 2026-03-31
T. Rowe Price Associates, Inc. Institution (13G, 5%+) 7,356,865 8.61% 2026-09-30
Blackrock Inc. Institution (13F) 7,192,446 8.42% 2026-09-30
Vestal Point Capital, LP Institution (13G, 5%+) 7,130,000 8.34% 2026-09-30
Ali Behbahani
Director · +78,600 options
Insider 6,692,298 7.83% 2026-07-01
New Enterprise Associates 17, L.P. 5%+ holder (13D) 6,692,298 7.83% 2026-07-01
NEA Management Company, LLC Institution (13F) 6,692,298 7.83% 2026-09-30
Adam Goulburn 5%+ holder (13G) 6,513,765 7.62% 2026-03-31
Versant Venture Capital VI, L.P.
10% owner
Insider 5,652,922 6.62% 2024-10-28
BVF PARTNERS L P/IL Institution (13G, 5%+) 4,276,578 5.00% 2026-09-30
BVF Inc. Institution (13F) 4,276,578 5.00% 2026-09-30
TCG Crossover Management, LLC Institution (13F) 3,781,532 4.43% 2026-09-30

Share count 85,450,119 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-05
filed 2026-10-06
Bowen Matthew
Sale (S) 13 $10.56 25,891
2026-07-16
filed 2026-07-17
Warmuth Markus
Sale (S) 9,500 $23.18 585,038
2026-07-15
filed 2026-07-16
Champoux Jennifer
Option exercise (M) 4,351 – –
2026-07-15
filed 2026-07-16
Champoux Jennifer
Option exercise (M) 4,351 $3.98 66,722
2026-07-15
filed 2026-07-16
Champoux Jennifer
Sale (S) 4,351 $23.38 62,371

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full GLUE picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GLUE and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.